Clearmind Medicine Presents at FDA Psychedelics Hearing, Advocates for Non-Hallucinogenic Treatments
Event summary
- Clearmind Medicine's Chief of Global Impact, Mary-Elizabeth Gifford, presented at the FDA's historic psychedelics hearing on September 14, 2026.
- Gifford discussed patient access and shared insights from Clearmind’s clinical trials at Yale and Johns Hopkins.
- The hearing convened senior FDA officials and federal partners to evaluate the potential future therapeutic use of psychedelic drugs.
- Clearmind's MEAI, a non-hallucinogenic psychedelic-derived neuroplastogen, is in Phase 2a clinical trials for Alcohol Use Disorder (AUD).
- Approximately 1,800 participants attended the hearing in person and virtually.
The big picture
Clearmind Medicine's participation in the FDA's historic psychedelics hearing underscores the growing regulatory interest in non-hallucinogenic psychedelic-derived treatments. The company's focus on scalable patient access through existing healthcare infrastructure aligns with broader industry trends towards integrating psychedelic therapies into mainstream medical practice. The strategic significance lies in Clearmind's potential to reduce health disparities and improve access to treatments for intractable substance use disorders.
What we're watching
- Regulatory Dynamics
- How the FDA's stance on non-hallucinogenic psychedelics will impact Clearmind's regulatory pathway and approval timeline.
- Market Adoption
- Whether Clearmind can leverage existing primary care and VA resources to achieve scalable patient access for AUD treatments.
- Clinical Progress
- The pace at which Clearmind's MEAI advances through clinical trials and the potential for broader applications beyond AUD.
Related topics